gip/glp 1-agonist tirzepatide Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Bridging the gap between GLP1-receptor
Description
You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements
276 , R514R521 (1999)
SURMOUNT-MMO, NCT05556512) (Table 3)
Retrieved 23 January 2018
While rare complications like gastroparesis (stomach paralysis) or pancreatitis can occur, they are uncommon
